Acumen Medical Trials

At Manningham Medical Centre, you can find all the data about Acumen Medical Trials. We have collected data about general practitioners, medical and surgical specialists, dental, pharmacy and more. Please see the links below for the information you need.

Acumen Publishes Phase 1 Trial Design and Clinical …

https://finance.yahoo.com/news/acumen-publishes-phase-1-trial-120000190.html

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that …

Acumen Announces First Patient Dosed in a Phase 1 Clinical …

https://finance.yahoo.com/news/acumen-announces-first-patient-dosed-120000675.html

ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers …

Acumen Pharmaceuticals to Present Clinical Trial Design …

https://www.globenewswire.com/news-release/2021/11/02/2325333/0/en/Acumen-Pharmaceuticals-to-Present-Clinical-Trial-Design-for-INTERCEPT-AD-the-Phase-1-Placebo-Controlled-Single-and-Multiple-Dose-Clinical-Trial-of-ACU193-at-2021-Clinical-Trials-on.html

Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic …

ACU193 | Acumen Pharma

https://acumenpharm.com/acu193/

ACU193, our lead therapeutic candidate, is an anti-amyloid-beta oligomer (AβO) monoclonal antibody (mAb) with best-in-class potential for efficacy and safety in Alzheimer’s disease. It has been designed to have disease …

INTERCEPT-AD | Acumen Pharma

https://acumenpharm.com/intercept-ad/

Acumen has initiated a first-in-human, Phase 1 clinical trial of ACU193 in early Alzheimer’s patients. This study, named INTERCEPT-AD, is a single ascending dose (SAD) and …

Acumen Pharmaceuticals to Present Clinical Trial Design for

https://finance.yahoo.com/news/acumen-pharmaceuticals-present-clinical-trial-120000783.html

Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, …

Acumen - Clinical Trials Arena

https://www.clinicaltrialsarena.com/contractors/contract-research-organization/acumen/

Acumen provides clinical research and development services to pharmaceutical, biotechnology and medical device clients worldwide, supporting our clients in their drug …

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial …

https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-completes-enrollment-phase-1-trial-acu193

CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the …

A Study to Evaluate the Safety, Tolerability, and Blood …

https://clinicaltrials.gov/ct2/show/NCT04931459

Must meet all of the following clinical criteria for MCI due to AD or mild AD at Screening: Participant meets NIA-Alzheimer's Association (NIA-AA) criteria for MCI due …

Acumen Pharmaceuticals Announces Pricing of Upsized Initial

https://finance.yahoo.com/news/acumen-pharmaceuticals-announces-pricing-upsized-024400697.html

Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its …

Need more information about Acumen Medical Trials?

At Manningham Medical Centre, we collected data on more than just Acumen Medical Trials. There is a lot of other useful information. Visit the related pages or our most popular pages. Also check out our Doctors page.